Heart Failure
Heart failure is a condition in which the heart is not able to pump enough blood throughout the body for its normal function. The cause of this can be either functional or structural disorder of the heart. Common causes of heart failure include cardiomyopathy, hypertension, heart valve problems and coronary artery disease. There is no cure for heart failure.
The Scientific Rationale Behind Using Stem Cells To Treat Heart Failure
With respect to the heart, stem cells have the ability to not only home in to the damaged areas but also to initiate a cascade of biological events both of which culminate in healing of the heart muscle. For example, animal studies have demonstrated that stem cell therapy for heart failure will cause new muscle cells to be formed through stimulation of dormant stem cells that are already inside the heart muscle. In these studies, the administered stem cell also transformed into new heart muscle cells.
At Stem Cell Institute, our stem cell treatment protocol for heart failure involves administration of mesenchymal stem cells harvested from human umbilical cord tissue.
Through administration of mesenchymal stem cells, we have observed improvements in heart failure patients treated at our facilities.
Read Dr. Riordan’s book “Stem Cell Therapy: A Rising Tide”
“Neil takes readers on a riveting journey through the past, present, and future of stem cell therapy. His well-researched, educational, and entertaining book could change your life. I highly recommend it.”
– Tony Robbins, NY Times #1 Bestselling Author
Stem Cells for Osteoarthritis: James’s Story
Osteoarthritis
Stem Cells for Osteoarthritis: James’s Story
Osteoarthritis
UFC Champion TJ Dillashaw discusses how stem cell therapy in Panama cleared up his psoriasis
Sports Injuries
UFC Champion TJ Dillashaw discusses how stem cell therapy in Panama cleared up his psoriasis
Sports Injuries
Stem cell treatments for autism: Kenneth Kelley
Autism
Stem cell treatments for autism: Kenneth Kelley
Autism
What are the advantages of treating heart failure with allogeneic umbilical cord tissue-derived stem cells?
No need to collect stem cells from the patient’s hip bone or fat under anesthesia, which can be an unpleasant ordeal.
There is a growing body of evidence showing that umbilical cord tissue-derived (HUCT) mesenchymal stem cells are more robust than mesenchymal stem cells from other sources.
No need to administer chemotherapy drugs like granulocyte-colony stimulating factor (G-CSF or GCSF) to stimulate the bone marrow to produce granulocytes and stem cells, and release them into the bloodstream.
Since HUCT mesenchymal stem cells are immune system privileged, cell rejection is not an issue and Human Leukocyte Antigen (HLA) matching is not necessary.
The stem cells with the best anti-inflammatory activity, immune modulating capacity, and ability to stimulate regeneration can be screened and selected.
Allogeneic stem cells can be administered multiple times over the course of days in uniform dosages that contain high cell counts.
Umbilical cord tissue provides an abundant supply of mesenchymal stem cells.
We use Golden Cells™. Years-long retrospective analysis of patient outcomes has enabled us to identify and select the best cells for use in our patients.
Heart Failure Treatment Protocols
One of our staff physicians will assign a stem cell treatment protocol after you have submitted all requested medical information and received approval. Your recommended protocol may differ
Protocol
Treatment length: 5 Nights
Physical examination and blood testing: Day 1
3 intravenous infusions + intramuscular injections of specially selected human umbilical cord tissue-derived allogeneic mesenchymal stem cells (Golden Cells™): Days 2 – 4
Your questions, answered.
Get answers to frequently asked questions about stem cell therapy, including information on stem cell sources, collection methods, treatment procedures, safety protocols, and more.
No stem cell product from any source, including the patient’s own, is approved by the US FDA to treat heart failure.
However, human umbilical cord tissue-derived mesenchymal stem cells that were isolated and grown in our laboratory in Panama to create master cell banks have been used in the United States under US FDA regulation.
These cells served as the starting material for cellular products used in MSC clinical trials for two Duchenne’s muscular dystrophy patients under US FDA’s designation of Investigational New Drug (IND) for single-patient compassionate use. (IND 16026 DMD Single Patient).
The body’s immune system is unable to recognize umbilical cord-derived mesenchymal stem cells as foreign, and therefore they are not rejected. Human umbilical cord tissue stem cells have been administered tens of thousands of times at the Stem Cell Institute, and there has never been a single instance of rejection (graft vs. host disease). As a matter of fact, allogeneic (not the patient’s own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Umbilical cord-derived mesenchymal stem cells also proliferate/differentiate more efficiently than “older” cells, such as those found in the fat, and therefore, they are considered to be more “potent”.
The adult stem cells used to treat heart failure at the Stem Cell Institute come from human umbilical cord tissue (allogeneic mesenchymal). These stem cells are expanded at Medistem Panama’s state-of-the-art laboratory.
The mesenchymal stem cells we use are recovered from donated umbilical cords following normal, healthy births. Each mother has her medical history screened and is tested for infectious diseases. Proper consent is received from each family prior to donation.
All umbilical cord-derived stem cells are screened for infectious diseases to International Blood Bank Standards before they are cleared for use in patients.
Only a small percentage of donated umbilical cords pass our rigorous screening process.
Proper follow-up is an essential part of stem cell therapy. Our primary goal is to ensure that you are progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 6 months, 9 months, and 1 year to monitor your child’s progress.
You can apply today to find out if you are eligible for treatment. You may also contact us by telephone 1 (800) 980-7836 (toll-free in US) and 1 (954) 358-3382 (International).